Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT05725772 Completed - Parkinson Disease Clinical Trials

Comparison of Health Care Delivery Methods in Parkinson's Disease

Start date: December 13, 2022
Phase:
Study type: Observational

The goal of this observational study is to compare the ability to perform telemedicine visits at home, at a regional clinic close to home, and in-person in People with Parkinson's disease. The main question it aims to answer is whether telemedicine assessments provide high quality care to people with Parkinson's disease. Participants will perform a regular clinic visit followed by research evaluations of their disease. Researchers will compare the results of these assessments at the different visit types to see if there are differences in the results.

NCT ID: NCT05713500 Completed - Parkinson Disease Clinical Trials

Comparative Study of Personality in Parkinson's Disease Patients With Other Chronic Pain

PSYCHO-PAIN
Start date: February 16, 2023
Phase:
Study type: Observational

The present study compare personality of Parkinson's Disease (PD) patients with chronic, PD patients without pain and non-parkinsonian patients with other chronic pain condition.

NCT ID: NCT05700838 Completed - Parkinson Disease Clinical Trials

Refining Cough Skill Training in Parkinson's Disease and Dysphagia

Start date: September 21, 2022
Phase: Phase 1
Study type: Interventional

Airway protection deficits (cough and swallowing) are prevalent and pervasive in Parkinson's disease (PD), contributing to adverse health outcomes like pneumonia. This study aims to refine cough skill training by examining whether variable versus constant practice conditions improve cough outcomes in people with PD. In addition, this study will provide insight into optimal respiratory adaptations that occur during training to support cough effectiveness, resulting in immediately translatable treatments to improve airway protection-related health outcomes in people with neurodegenerative disease.

NCT ID: NCT05699161 Completed - Clinical trials for Idiopathic Parkinson Disease

Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson

SVFP1
Start date: October 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an interventional study to treat 10 patients with a diagnosis of Parkinson's disease with neurological assessment from the Oxford Parkinson's Disease Quotient-39 (PDQ-39) and Movement Disorders Society Universal Parkinson's Disease Rating Scale (MDS-UPDRS), with autologous adipose tissue-derived stromal vascular fraction (SVF) cells by subdermal plane injection into the submuscular aponeurotic fascia of the face. This study assesses: 1) safety and 2) feasibility and 3) exploratory evidence of efficacy.

NCT ID: NCT05690308 Completed - Parkinson Disease Clinical Trials

Visual Perturbation Training to Reduce Fall Risk in People With Parkinson's Disease

Vesti-PD
Start date: December 20, 2022
Phase: N/A
Study type: Interventional

Falls during walking are common in people with Parkinson's Disease (PD). Fall risk can be attributed in part to the loss of automaticity in walking and an increased reliance on sensory cues, such as the input from the balance organ. In this project the investigators want to assess the effectiveness of rehabilitation training aiming to improve this vestibular input. The effects of a visual perturbation training in a virtual reality environment will be compared to conventional treadmill training.

NCT ID: NCT05687799 Completed - Clinical trials for Idiopathic Parkinson's Disease

Fatigue, Sleep and Quality of Life in Parkinson's Patients

Start date: December 22, 2022
Phase:
Study type: Observational

Parkinson's Disease (PD) is a neurodegenerative disease characterized by chronic and progressive loss of dopaminergic neurons in the substantia nigra (SN) pars compacta. Sleep disturbances and fatigue are very common problems in Parkinson's patients. He reported that the frequency of fatigue was 47% in patients with a disease duration of less than five years and 70% in patients with a disease duration of more than five years. Fatigue in PD has been found to be associated with decreased physical activity, decreased functionality, sleep disorders, gait disturbances, motor findings, autonomic findings, increased levodopa dose, and motor fluctuations. Motor and non-motor symptoms in Parkinson's patients affect the individual's ability to perform activities of daily living independently. Impairments in functional status lead to negative consequences on quality of life. PD affects the individual not only physically, but also psychologically and socially.The neutrophil/lymphocyte ratio is a marker of peripheral inflammation. The relationship of peripheral inflammation to quality of sleep, quality of life and fatigue in individuals is unclear. The aim of this study was to investigation fatigue, quality of sleep and quality of life, and the relationship between neutrophil/lymphocyte ratio in Parkinson's patients.

NCT ID: NCT05683925 Completed - Parkinson Disease Clinical Trials

Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Characteristics in Parkinson's Disease

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

In this randomised placebo-controlled trial, the investigators will include 30 PD (Parkinson's disease) patients with HY (Hoehn Yahr stage) >2 and L-dopa unresponsive gait characteristics. Each participant will receive taVNS at 25Hz, taVNS at 100Hz and sham VNS (sVNS). During each stimulation, different gait characteristics will be measured with wearable insertion motion sensors.

NCT ID: NCT05683665 Completed - Parkinson Disease Clinical Trials

DaTSCAN Brain Scintigraphy and Psychotropic Treatments: Influence on Radiotracer Binding

DAPSYFIX
Start date: April 1, 2023
Phase:
Study type: Observational

DaTSCAN™ (123I-ioflupnae) tomoscintigraphy assesses the density of dopamine transporters (DATs) on the presynaptic membrane of dopaminergic neurons. This examination is used in clinical routine in patients presenting a parkinsonian syndrome in search of a pre-synaptic dopaminergic denervation pointing to a neurodegenerative origin of this syndrome To date, there is little literature data evaluating the influence of psychotropic treatments frequently used in clinical routine on DaTSCAN™ CT images. Some studies have shown that SSRI (selective serotonin reuptake inhibitor) and SNRI (serotonin and norepinephrine reuptake inhibitor) antidepressants can significantly alter striatal ioflupane uptake ratios (10-20%) with no obvious influence on the visual interpretation of the examination . The objective of this study was to evaluate the influence of the most commonly used psychotropic therapies, sometimes in combination, on DaTSCAN™ CT images with a large population of patients included in clinical routine.

NCT ID: NCT05680571 Completed - Parkinson Disease Clinical Trials

Validation of Bulbicam for Parkinson- and Ataxia-patients

Start date: December 19, 2022
Phase:
Study type: Observational

Aim is to investigate repeatability and stability of four Neurological-related Bulbicam tests in patients suffering Parkinson (PD),Ataxia (AT) and matched healthy control (HC). Study population The study consists of the patients suffering from PD or AT and HV of both genders above 18 years of age without any eye- or neurological disorder. Bulbicam will be used in the study and five tests will be performed The study will be performed as a controlled, open and non-randomized, stratified observational single center. The stratification factors will be pathology (PD&AT) and internal classifications. ed. The main variables will be the variables recorded at the four Bulbicam tests and the standard neuro-ophthalmological variables included for PD and AT Participants, who fulfil the inclusion criteria; do not meet any of the exclusion criteria and willing to give informed consent to participate will receive an appointment for starting the study. During the first day of the study, the included patients will undergo a neuro-ophthalmological examination by a neurologist. Additionally, Bulbicam examination will be performed twice with a rest period of one hour between each registration. The healthy controls will only undergo a standard examination and twice BulbiCam examination. The controls will only participate one day. The patients will participate two more days with two Bulbicam examinations per day. Sample size: Sixteen PD-patients ,16 AT-patients and 32 HCs will be included in the study.

NCT ID: NCT05678725 Completed - tDCS Clinical Trials

Transcranial Direct/ Alternating Current Stimulation for Parkinson's Disease Treatment

Start date: February 15, 2023
Phase: N/A
Study type: Interventional

To investigate the difference in the treatment efficacy between transcranial direct current stimulation and transcranial alternating current stimulation on Parkinson's disease, including the improvements in the motor, cognitive, and underlying neural mechanisms behind differences in efficacy by electroencephalography (EEG).